Zoetis (ZTS) Cash from Financing Activities (2012 - 2026)
Zoetis (ZTS) posted quarterly Cash from Financing Activities of -$840.0 million for Q1 2026, down 24.08% year-over-year from -$1.1 billion in Q1 2025, and down 69.7% quarter-over-quarter from -$495.0 million in Q4 2025.
Zoetis (ZTS) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Cash from Financing Activities for 15 consecutive years, with -$840.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 24.08% year-over-year to -$840.0 million; the TTM figure through Mar 2026 stood at -$2.0 billion (up 27.73% YoY), while the FY2025 annual figure was -$1.9 billion, up 29.7% from the prior year.
- Cash from Financing Activities slipped to -$840.0 million in Q1 2026 per ZTS's latest filing, from -$495.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $780.0 million in Q4 2022 and bottomed at -$1.8 billion in Q1 2023.
- Historically, Cash from Financing Activities has averaged -$551.9 million across 5 years, with a median of -$545.0 million in 2022.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 348.41% — and 2023, when it sank 230.64%.
- Zoetis' Cash from Financing Activities stood at $780.0 million in 2022, then sank by 150.9% to -$397.0 million in 2023, then slumped by 87.66% to -$745.0 million in 2024, then soared by 33.56% to -$495.0 million in 2025, then tumbled by 69.7% to -$840.0 million in 2026.
- Business Quant data shows ZTS's Cash from Financing Activities at -$840.0 million in Q1 2026, -$495.0 million in Q4 2025, and -$134.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 17.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -813.00 Mn |
| Jun 30, 2026 | -813.00 Mn |
| Mar 31, 2026 | -840.00 Mn |
| Mar 31, 2026 | -840.00 Mn |
| Dec 31, 2025 | -495.00 Mn |
| Dec 31, 2025 | -495.00 Mn |
| Sep 30, 2025 | -134.00 Mn |
| Sep 30, 2025 | -134.00 Mn |
| Jun 30, 2025 | -564.00 Mn |
| Jun 30, 2025 | -564.00 Mn |
| Mar 31, 2025 | -677.00 Mn |
| Mar 31, 2025 | -677.00 Mn |
| Dec 31, 2024 | -745.00 Mn |
| Dec 31, 2024 | -745.00 Mn |
| Sep 30, 2024 | -628.00 Mn |
| Sep 30, 2024 | -628.00 Mn |
| Jun 30, 2024 | -763.00 Mn |
| Jun 30, 2024 | -763.00 Mn |
| Mar 31, 2024 | -524.00 Mn |
| Mar 31, 2024 | -524.00 Mn |